INIS
patients
100%
inflammation
51%
immunoglobulins
44%
fibers
39%
pain
23%
assessments
21%
diseases
18%
doses
15%
sodium
15%
maintenance
13%
safety
12%
data
10%
chemotherapy
10%
motors
9%
mutations
9%
clinical trials
9%
genes
8%
evaluation
7%
brain
7%
comparative evaluations
7%
genetics
6%
netherlands
6%
reliability
6%
symptoms
6%
levels
5%
quality of life
5%
fatigue
5%
validation
5%
reviews
5%
proteins
5%
Keyphrases
Small Fiber Neuropathy
42%
Chronic Inflammatory Demyelinating Polyneuropathy
36%
Intravenous Immunoglobulin (IVIg)
24%
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
15%
Subcutaneous Immunoglobulin
14%
Rasch
13%
Nav1.7
12%
Disability Scale
11%
IgPro20
10%
PATH Study
10%
Myotonic Dystrophy
10%
Chemotherapy-induced Peripheral Neuropathy
10%
Hizentra
9%
Maintenance Treatment
9%
Polyneuropathy
9%
Placebo
9%
Clinical Trials
8%
Sodium Channel
8%
Facioscapulohumeral muscular Dystrophy
7%
Inflammatory Neuropathy
7%
Neuropathy
7%
Neuropathic Pain
6%
SCN9A
6%
Minimal Clinically Important Difference
6%
IV Immunoglobulin
6%
Grip Strength
6%
Netherlands
6%
Randomized Controlled Trial
6%
Long-term Efficacy
5%
Activities of Daily Living
5%
Medicine and Dentistry
Small Fiber Neuropathy
30%
Immunoglobulin
26%
Chronic Inflammatory Demyelinating Polyneuropathy
23%
Neuropathy
20%
Placebo
9%
Human Immunoglobulin
8%
Maintenance Therapy
7%
Polyradiculoneuropathy
7%
Immunoglobulin M
7%
Randomized Controlled Trial
6%
Clinical Trial
6%
Sodium Channel
6%
Diseases
5%
Polyneuropathy
5%
Quality of Life
5%
Myotonic Dystrophy
5%
Diabetic Neuropathy
5%
Lacosamide
5%
Facioscapulohumeral Muscular Dystrophy
5%
Neuropathic Pain
5%